Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

PURPOSE: We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma. METHODS: A total of 1,873 women with incompletely resected stage III to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tewari, Krishnansu S., Burger, Robert A., Enserro, Danielle, Norquist, Barbara M., Swisher, Elizabeth M., Brady, Mark F., Bookman, Michael A., Fleming, Gini F., Huang, Helen, Homesley, Howard D., Fowler, Jeffrey M., Greer, Benjamin E., Boente, Matthew, Liang, Sharon X., Ye, Chenglin, Bais, Carlos, Randall, Leslie M., Chan, John K., Ferriss, J. Stuart, Coleman, Robert L., Aghajanian, Carol, Herzog, Thomas J., DiSaia, Philip J., Copeland, Larry J., Mannel, Robert S., Birrer, Michael J., Monk, Bradley J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6879307/
https://ncbi.nlm.nih.gov/pubmed/31216226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados